Triple Moving Average Crossover
Previous Close | 29.32 |
Open | 29.11 |
Bid | 28.74 x 800 |
Ask | 28.80 x 900 |
Day's Range | 28.56 - 29.20 |
52 Week Range | 21.75 - 32.23 |
Volume | |
Avg. Volume | 1,235,259 |
Market Cap | 4.811B |
Beta (5Y Monthly) | 0.61 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.00 |
Earnings Date | Apr 26, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 35.33 |
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alkermes plc (Nasdaq: ALKS) (the Company) today filed its definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) and issued a letter to its shareholders in connection with the Company's upcoming 2023 Annual General Meeting of Shareholders (the Annual Meeting), which is scheduled to be held on June 29, 2023. The letter details the Company's successful execution and value creation since the announcement of its Value Enhancement Plan in December 2020. The Value Enhancemen
Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry portfolio—which includes LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—at four scientific conferences this spring. Several of these meetings coincide with Mental Health Awareness Month in May, an important moment in the year that provides an opportunity to raise awareness about mental health conditions, support the millions of people living with these complex diseases,
Alkermes plc (Nasdaq: ALKS) today announced the acceptance of two abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago June 2-6, 2023. Trial-in-progress posters from the actively recruiting phase 2 ARTISTRY-6 clinical trial and phase 3 ARTISTRY-7 clinical trial will be presented. ARTISTRY-6 is eva
Alkermes plc (Nasdaq: ALKS) today filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (SEC) in connection with its upcoming Annual General Meeting of Shareholders (the Annual Meeting). The company also provided an update on its annual director nomination process and its ongoing shareholder engagement efforts. The preliminary proxy statement is available on the Investor Relations section of the company's website at www.alkermes.com.
NORTHAMPTON, MA / ACCESSWIRE / May 8, 2023 / Alkermes Alkermes is proud to be selected as a 2023 Top 100 Companies Leading in Wellbeing by Ibec! This recognition acknowledges companies in Ireland who are leading the way in supporting employee wellbeing. ...
With a price-to-sales (or "P/S") ratio of 4.4x Alkermes plc ( NASDAQ:ALKS ) may be sending very bullish signals at the...
Alkermes' Athlone site was recently shortlisted for gradireland's 17th annual Graduate Recruitment Awards! This award recognizes outstanding graduate intake programs across Ireland.
Alkermes Athlone site recently received a 2023 award in the Life Sciences category at Ireland's 2023 Health & Safety Excellence Awards. This recognition is a testament to our employees' focus on building a culture of safety and risk management in Athlone.
The 2023 Alkermes Inspiration Grants® program is now open for applications! These grants are designed to support programs or organizations for people affected by serious mental illness, addiction and cancer.
Alkermes (ALKS) reports encouraging first-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.
Patients diagnosed with platinum-resistant Ovarian Cancer (PROC) often face poor prognosis due to the limited treatment options.
Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alkermes (ALKS) delivered earnings and revenue surprises of 133.33% and 1.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2023.
Alkermes plc (Nasdaq: ALKS) today announced that on April 19, 2023 it received a second interim award (the "Second Interim Award") from the arbitral tribunal (the "Tribunal") in its arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V. ("Janssen"), a subsidiary of Johnson & Johnson.
Last week, Katie Joyce, VP of Corporate Affairs, participated in a panel discussion at this year's Women in Bio (WIB) Management Track event featuring women leaders in life science. This year's event gave attendees the opportunity to connect with industry leaders and hear from a panel of executive women leaders discussing their career paths and individual experiences.
Alkermes plc (Nasdaq:ALKS) recently announced that the company will accept applications for its Alkermes Inspiration Grants® program beginning on May 1, 2023.
NORTHAMPTON, MA / ACCESSWIRE / April 20, 2023 / Alkermes Alcohol Use Disorder (AUD) does not discriminate. But some communities are disproportionately affected. As we recognize both National Minority Health Month and Alcohol Awareness Month, we ...
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, April 26, 2023 to discuss the company's first quarter financial results.
With the business potentially at an important milestone, we thought we'd take a closer look at Alkermes plc's...
Alkermes plc (Nasdaq: ALKS) today announced that it has submitted a confidential draft Form 10 registration statement to the United States Securities and Exchange Commission in connection with the previously announced planned separation of the company's oncology business into an independent, publicly-traded company (Oncology Co.). The company continues to expect to complete the separation in the second half of 2023.
NORTHAMPTON, MA / ACCESSWIRE / April 12, 2023 / Alkermes (NASDAQ:ALKS) As part of last month's observance of Equal Pay Day , Alkermes reaffirms our commitment to closing long-standing pay gaps between men and women. We are proud of our efforts to ...
By buying an index fund, investors can approximate the average market return. But if you buy good businesses at...